Tigatuzumab

From Self-sufficiency

Revision as of 19:24, 5 April 2010 by Anypodetos (Talk) (Added mab_type, updated source; spelled out abbr)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Tigatuzumab
Monoclonal antibody
Type	Whole antibody
Source	Template:Infobox drug/mab source
Target	TNFRSF10B (TRAIL-R2)
Identifiers
CAS Number	918127-53-4
ATC code	none
Chemical data
Formula	C₆₄₀₆H₉₉₂₄N₁₇₁₆O₂₀₁₂S₄₆
Molar mass	144.6 kDa[[Script error: No such module "String".]]

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Tigatuzumab (CS-1008) is a monoclonal antibody^[1] for the treatment of cancer. As of October 2009^[update], a clinical trial for the treatment of pancreatic cancer has been completed,^[2] Phase II trials for colorectal cancer^[3] and non-small cell lung cancer^[4] are running, and a study for ovarian cancer has been approved.^[5]

The drug targets member 10b of the tumor necrosis factor receptor superfamily (TNFRSF10B, better known as death receptor 5 or trail receptor 2), a protein overexpressed in many kinds of tumour.^[6]

References

v t e Humanized monoclonal antibodies ("-zu-")
"-tuzu-" (tumor)	Afutuzumab, Alemtuzumab, Bevacizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Citatuzumab bogatox, Dacetuzumab, Elotuzumab^†, Etaracizumab, Farletuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab^§, Milatuzumab, Nimotuzumab, Oportuzumab monatox, Pertuzumab, Sibrotuzumab, Tacatuzumab tetraxetan, Tigatuzumab, Trastuzumab, Tucotuzumab celmoleukin, Veltuzumab
"-lizu-" (immune system)	immunosuppressive: Aselizumab, Apolizumab, Benralizumab^†, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, PRO 140^†, Reslizumab, Rontalizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Vedolizumab, Visilizumab, TGN1412^§ non-immunosuppressive: Ibalizumab^†
"-bazu-" (bacterial)	Tefibazumab^†
"-cizu-" (cardiovascular)	Alacizumab pegol, Bevacizumab/Ranibizumab, Etaracizumab, Tadocizumab
"-nezu-"/"-neuzu-" (nervous system)	Bapineuzumab^†, Solanezumab, Tanezumab
"-toxazu-" (toxin as target)	Urtoxazumab
"-vizu-" (viral)	Felvizumab, Motavizumab, Palivizumab
"-kizu-" (interleukin as target)	Lebrikizumab
"-anibizu-" (angiogenesis inhibitor)	Ranibizumab
^†Undergoing clinical trials. ^§Never marketed.

This monoclonal antibody-related article is a stub. You can help ssf by expanding it.